Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Standing thyroidectomy in 10 horses.

Marcatili M, Voss SJ, Pollock PJ.

Vet Surg. 2018 Jan;47(1):86-92. doi: 10.1111/vsu.12744. Epub 2017 Nov 8.

PMID:
29114900
2.

Evaluating an educational intervention to alleviate distress amongst men with newly diagnosed prostate cancer and their partners.

Hedden L, Wassersug R, Mahovlich S, Pollock P, Sundar M, Bell RH, Goldenberg L, Higano CS.

BJU Int. 2017 Nov;120(5B):E21-E29. doi: 10.1111/bju.13885. Epub 2017 May 17.

PMID:
28516513
3.

Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.

Edmondson RJ, Crosbie EJ, Nickkho-Amiry M, Kaufmann A, Stelloo E, Nijman HW, Leary A, Auguste A, Mileshkin L, Pollock P, MacKay HJ, Powell ME, Bosse T, Creutzberg CL, Kitchener HC.

Gynecol Oncol. 2017 Aug;146(2):327-333. doi: 10.1016/j.ygyno.2017.05.014. Epub 2017 May 13.

PMID:
28511869
4.

hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases.

Ashton NW, Paquet N, Shirran SL, Bolderson E, Kariawasam R, Touma C, Fallahbaghery A, Gamsjaeger R, Cubeddu L, Botting C, Pollock PM, O'Byrne KJ, Richard DJ.

DNA Repair (Amst). 2017 Jun;54:30-39. doi: 10.1016/j.dnarep.2017.03.006. Epub 2017 Apr 6.

5.

Angiographic anatomy of the extracranial and intracranial portions of the internal carotid arteries in donkeys.

Khairuddin NH, Sullivan M, Pollock PJ.

Ir Vet J. 2017 Apr 20;70:12. doi: 10.1186/s13620-017-0090-0. eCollection 2017.

6.

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.

Eggink FA, Van Gool IC, Leary A, Pollock PM, Crosbie EJ, Mileshkin L, Jordanova ES, Adam J, Freeman-Mills L, Church DN, Creutzberg CL, De Bruyn M, Nijman HW, Bosse T.

Oncoimmunology. 2016 Dec 9;6(2):e1264565. doi: 10.1080/2162402X.2016.1264565. eCollection 2017.

7.

FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

Jeske YW, Ali S, Byron SA, Gao F, Mannel RS, Ghebre RG, DiSilvestro PA, Lele SB, Pearl ML, Schmidt AP, Lankes HA, Ramirez NC, Rasty G, Powell M, Goodfellow PJ, Pollock PM.

Gynecol Oncol. 2017 May;145(2):366-373. doi: 10.1016/j.ygyno.2017.02.031. Epub 2017 Mar 15.

PMID:
28314589
8.

Treatment of septic arthritis of the coxofemoral joint in 12 foals.

Barceló Oliver F, Russell TM, Uprichard KL, Neil KM, Pollock PJ.

Vet Surg. 2017 May;46(4):530-538. doi: 10.1111/vsu.12621. Epub 2017 Feb 15.

PMID:
28198553
9.

PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.

Packer LM, Geng X, Bonazzi VF, Ju RJ, Mahon CE, Cummings MC, Stephenson SA, Pollock PM.

Mol Cancer Ther. 2017 Apr;16(4):637-648. doi: 10.1158/1535-7163.MCT-16-0415. Epub 2017 Jan 23.

10.

Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation.

Karlsson T, Krakstad C, Tangen IL, Hoivik EA, Pollock PM, Salvesen HB, Lewis AE.

Oncotarget. 2017 Jan 17;8(3):3881-3894. doi: 10.18632/oncotarget.13989.

11.

Loss of Rearranged L-Myc Fusion (RLF) results in defects in heart development in the mouse.

Bourke LM, Del Monte-Nieto G, Outhwaite JE, Bharti V, Pollock PM, Simmons DG, Adam A, Hur SS, Maghzal GJ, Whitelaw E, Stocker R, Suter CM, Harvey RP, Harten SK.

Differentiation. 2017 Mar - Apr;94:8-20. doi: 10.1016/j.diff.2016.11.004. Epub 2016 Dec 5.

PMID:
27930960
12.

Challenges in Designing Psychological Treatment Studies for Sexual Dysfunction.

Brotto LA, Basson R, Chivers ML, Graham CA, Pollock P, Stephenson KR.

J Sex Marital Ther. 2017 Apr 3;43(3):191-200. doi: 10.1080/0092623X.2016.1212294. Epub 2016 Jul 14. No abstract available.

PMID:
27414090
13.

The "melanoma-enriched" microRNA miR-4731-5p acts as a tumour suppressor.

Stark MS, Tom LN, Boyle GM, Bonazzi VF, Soyer HP, Herington AC, Pollock PM, Hayward NK.

Oncotarget. 2016 Aug 2;7(31):49677-49687. doi: 10.18632/oncotarget.10109.

14.

A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding.

Painter JN, Kaufmann S, O'Mara TA, Hillman KM, Sivakumaran H, Darabi H, Cheng THT, Pearson J, Kazakoff S, Waddell N, Hoivik EA, Goode EL, Scott RJ, Tomlinson I, Dunning AM, Easton DF, French JD, Salvesen HB, Pollock PM, Thompson DJ, Spurdle AB, Edwards SL.

Am J Hum Genet. 2016 Jun 2;98(6):1159-1169. doi: 10.1016/j.ajhg.2016.04.012.

15.

Tamoxifen in men: a review of adverse events.

Wibowo E, Pollock PA, Hollis N, Wassersug RJ.

Andrology. 2016 Sep;4(5):776-88. doi: 10.1111/andr.12197. Epub 2016 May 6. Review.

16.

The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis.

Stark MS, Klein K, Weide B, Haydu LE, Pflugfelder A, Tang YH, Palmer JM, Whiteman DC, Scolyer RA, Mann GJ, Thompson JF, Long GV, Barbour AP, Soyer HP, Garbe C, Herington A, Pollock PM, Hayward NK.

EBioMedicine. 2015 May 12;2(7):671-80. doi: 10.1016/j.ebiom.2015.05.011. eCollection 2015 Jul.

17.

Angiographic Variation of the Internal Carotid Artery and its Branches in Horses.

Khairuddin NH, Sullivan M, Pollock PJ.

Vet Surg. 2015 Aug;44(6):784-9. doi: 10.1111/vsu.12357. Epub 2015 Jul 1.

PMID:
26138436
18.

miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma.

Stark MS, Bonazzi VF, Boyle GM, Palmer JM, Symmons J, Lanagan CM, Schmidt CW, Herington AC, Ballotti R, Pollock PM, Hayward NK.

Oncotarget. 2015 Jul 10;6(19):17753-63.

19.

Paralog-Specific Kinase Inhibition of FGFR4: Adding to the Arsenal of Anti-FGFR Agents.

Packer LM, Pollock PM.

Cancer Discov. 2015 Apr;5(4):355-7. doi: 10.1158/2159-8290.CD-15-0246.

20.

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.

Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, Leary A, Edmondson RJ, Powell ME, Crosbie EJ, Kitchener HC, Mileshkin L, Pollock PM, Smit VT, Creutzberg CL.

Mod Pathol. 2015 Jun;28(6):836-44. doi: 10.1038/modpathol.2015.43. Epub 2015 Feb 27.

21.

In 2124, half of all men can count on developing prostate cancer.

Pollock PA, Ludgate A, Wassersug RJ.

Curr Oncol. 2015 Feb;22(1):10-2. doi: 10.3747/co.22.2102. No abstract available.

22.

Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk.

Painter JN, O'Mara TA, Batra J, Cheng T, Lose FA, Dennis J, Michailidou K, Tyrer JP, Ahmed S, Ferguson K, Healey CS, Kaufmann S, Hillman KM, Walpole C, Moya L, Pollock P, Jones A, Howarth K, Martin L, Gorman M, Hodgson S; National Study of Endometrial Cancer Genetics Group (NSECG); CHIBCHA Consortium, De Polanco MM, Sans M, Carracedo A, Castellvi-Bel S, Rojas-Martinez A, Santos E, Teixeira MR, Carvajal-Carmona L, Shu XO, Long J, Zheng W, Xiang YB; Australian National Endometrial Cancer Study Group (ANECS), Montgomery GW, Webb PM, Scott RJ, McEvoy M, Attia J, Holliday E, Martin NG, Nyholt DR, Henders AK, Fasching PA, Hein A, Beckmann MW, Renner SP, Dörk T, Hillemanns P, Dürst M, Runnebaum I, Lambrechts D, Coenegrachts L, Schrauwen S, Amant F, Winterhoff B, Dowdy SC, Goode EL, Teoman A, Salvesen HB, Trovik J, Njolstad TS, Werner HM, Ashton K, Proietto T, Otton G, Tzortzatos G, Mints M, Tham E; RENDOCAS, Hall P, Czene K, Liu J, Li J, Hopper JL, Southey MC; Australian Ovarian Cancer Study (AOCS), Ekici AB, Ruebner M, Johnson N, Peto J, Burwinkel B, Marme F, Brenner H, Dieffenbach AK, Meindl A, Brauch H; GENICA Network, Lindblom A, Depreeuw J, Moisse M, Chang-Claude J, Rudolph A, Couch FJ, Olson JE, Giles GG, Bruinsma F, Cunningham JM, Fridley BL, Børresen-Dale AL, Kristensen VN, Cox A, Swerdlow AJ, Orr N, Bolla MK, Wang Q, Weber RP, Chen Z, Shah M, French JD, Pharoah PD, Dunning AM, Tomlinson I, Easton DF, Edwards SL, Thompson DJ, Spurdle AB.

Hum Mol Genet. 2015 Mar 1;24(5):1478-92. doi: 10.1093/hmg/ddu552. Epub 2014 Nov 6.

23.

Diagnosis and treatment of dynamic collapse of the cricotracheal ligament in thoroughbred racehorses.

Kelly PG, Pollock PJ.

Vet Surg. 2015 Feb;44(2):162-7. doi: 10.1111/j.1532-950X.2014.12262.x. Epub 2014 Aug 13.

PMID:
25124933
24.

A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

Powell MA, Sill MW, Goodfellow PJ, Benbrook DM, Lankes HA, Leslie KK, Jeske Y, Mannel RS, Spillman MA, Lee PS, Hoffman JS, McMeekin DS, Pollock PM.

Gynecol Oncol. 2014 Oct;135(1):38-43. doi: 10.1016/j.ygyno.2014.07.083. Epub 2014 Jul 11.

25.

A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).

Huddart RA, Gabe R, Cafferty FH, Pollock P, White JD, Shamash J, Cullen MH, Stenning SP; TE23 Trial Management Group and Collaborators; National Cancer Research Institute Testis Cancer Clinical Studies Group.

Eur Urol. 2015 Mar;67(3):534-43. doi: 10.1016/j.eururo.2014.06.034. Epub 2014 Jul 4.

26.

The antimicrobial activity of honey against common equine wound bacterial isolates.

Carnwath R, Graham EM, Reynolds K, Pollock PJ.

Vet J. 2014 Jan;199(1):110-4. doi: 10.1016/j.tvjl.2013.07.003. Epub 2013 Aug 17.

PMID:
23962613
27.

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.

Byron SA, Chen H, Wortmann A, Loch D, Gartside MG, Dehkhoda F, Blais SP, Neubert TA, Mohammadi M, Pollock PM.

Neoplasia. 2013 Aug;15(8):975-88.

28.

Dynamic ventrorostral displacement of the dorsal laryngeal mucosa in horses.

Pollock PJ, Kelly PG, Reardon RJ, Kelly GM.

Vet Rec. 2013 May 11;172(19):501. doi: 10.1136/vr.101319. Epub 2013 Apr 4.

PMID:
23559426
29.

Comparison of dynamic and resting endoscopy of the upper portion of the respiratory tract in 57 Thoroughbred yearlings.

Kelly PG, Reardon RJ, Johnston MS, Pollock PJ.

Equine Vet J. 2013 Nov;45(6):700-4. doi: 10.1111/evj.12061. Epub 2013 Mar 21.

PMID:
23521159
30.

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).

Langley RE, Cafferty FH, Alhasso AA, Rosen SD, Sundaram SK, Freeman SC, Pollock P, Jinks RC, Godsland IF, Kockelbergh R, Clarke NW, Kynaston HG, Parmar MK, Abel PD.

Lancet Oncol. 2013 Apr;14(4):306-16. doi: 10.1016/S1470-2045(13)70025-1. Epub 2013 Mar 4.

31.

Lineage-specific biomarkers predict response to FGFR inhibition.

Loch DC, Pollock PM.

Cancer Discov. 2012 Dec;2(12):1081-3. doi: 10.1158/2159-8290.CD-12-0486.

32.

Surgical treatment of septic physitis in 17 foals.

Hall MS, Pollock PJ, Russell T.

Aust Vet J. 2012 Dec;90(12):479-84. doi: 10.1111/j.1751-0813.2012.01000.x. Epub 2012 Oct 15.

PMID:
23186089
33.

Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.

Byron SA, Loch DC, Pollock PM.

Int J Gynecol Cancer. 2012 Nov;22(9):1517-26. doi: 10.1097/IGC.0b013e31826f6806.

PMID:
23060048
34.

XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts.

Doudican NA, Byron SA, Pollock PM, Orlow SJ.

Anticancer Drugs. 2013 Feb;24(2):181-8. doi: 10.1097/CAD.0b013e32835a43f1.

PMID:
23059386
35.

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.

Byron SA, Loch DC, Wellens CL, Wortmann A, Wu J, Wang J, Nomoto K, Pollock PM.

Mol Cancer. 2012 Oct 5;11:75. doi: 10.1186/1476-4598-11-75.

36.

A fresh look at vesicovaginal reflux in mares.

Pollock PJ.

Vet Rec. 2012 Jun 16;170(24):618-9. doi: 10.1136/vr.e4121. No abstract available.

PMID:
22710326
37.

Local anesthesia and hydro-distension to facilitate cystic calculus removal in horses.

Russell T, Pollock PJ.

Vet Surg. 2012 Jul;41(5):638-42. doi: 10.1111/j.1532-950X.2012.00986.x. Epub 2012 Mar 29.

PMID:
22463467
38.

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.

Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, Goodfellow PJ, Pollock PM.

PLoS One. 2012;7(2):e30801. doi: 10.1371/journal.pone.0030801. Epub 2012 Feb 23. Erratum in: PLoS One. 2012;7(2):doi/10.1371/annotation/0bfaecca-0f87-43fe-97cc-f2ae3ddeb6d5.

39.

Evoked otoacoustic emissions: an alternative test of auditory function in horses.

Mc Brearty A, Auckburally A, Pollock PJ, Penderis J.

Equine Vet J. 2013 Jan;45(1):60-5. doi: 10.1111/j.2042-3306.2011.00542.x. Epub 2012 Feb 2.

PMID:
22296459
40.

Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734.

Wortmann A, He Y, Christensen ME, Linn M, Lumley JW, Pollock PM, Waterhouse NJ, Hooper JD.

J Biol Chem. 2011 Dec 9;286(49):42303-15. doi: 10.1074/jbc.M111.227462. Epub 2011 Oct 12.

41.

Re: Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. M. R. Smith, R. A. Morton, K. G. Barnette, P. R. Sieber, S. B. Malkowicz, D. Rodriguez, M. L. Hancock and M. S. Steiner. J Urol 2010;184:1316-1321.

Langley RE, Cafferty FH, Pollock PA, Price P, Abel PD.

J Urol. 2011 Jun;185(6):2430-1; author reply 2431-2. doi: 10.1016/j.juro.2011.02.036. Epub 2011 Apr 22. No abstract available.

PMID:
21513954
42.

Targeting mutant fibroblast growth factor receptors in cancer.

Greulich H, Pollock PM.

Trends Mol Med. 2011 May;17(5):283-92. doi: 10.1016/j.molmed.2011.01.012. Epub 2011 Mar 1. Review.

43.

Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214).

Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Stenning SP.

J Clin Oncol. 2011 Mar 10;29(8):957-62. doi: 10.1200/JCO.2009.26.4655. Epub 2011 Jan 31.

PMID:
21282539
44.

Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up.

Mead GM, Fossa SD, Oliver RT, Joffe JK, Huddart RA, Roberts JT, Pollock P, Gabe R, Stenning SP; MRC/EORTC seminoma trial collaborators.

J Natl Cancer Inst. 2011 Feb 2;103(3):241-9. doi: 10.1093/jnci/djq525. Epub 2011 Jan 6.

PMID:
21212385
45.

Association of owner-reported noise with findings during dynamic respiratory endoscopy in Thoroughbred racehorses.

Witte SH, Witte TH, Harriss F, Kelly G, Pollock P.

Equine Vet J. 2011 Jan;43(1):9-17. doi: 10.1111/j.2042-3306.2010.00152.x.

PMID:
21143628
46.

Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: an increasing but under-recognised problem.

Langley R, Price P, Pollock P, Abel PD.

BJU Int. 2010 Sep;106(5):726-7; author reply 727. doi: 10.1111/j.1464-410X.2010.09605_1.x. No abstract available.

47.

Radiographic evaluation of the modified Brunelli technique versus the Blatt capsulodesis for scapholunate dissociation in a cadaver model.

Pollock PJ, Sieg RN, Baechler MF, Scher D, Zimmerman NB, Dubin NH.

J Hand Surg Am. 2010 Oct;35(10):1589-98. doi: 10.1016/j.jhsa.2010.06.029.

PMID:
20888495
48.

p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation.

Terzian T, Torchia EC, Dai D, Robinson SE, Murao K, Stiegmann RA, Gonzalez V, Boyle GM, Powell MB, Pollock PM, Lozano G, Robinson WA, Roop DR, Box NF.

Pigment Cell Melanoma Res. 2010 Dec;23(6):781-94. doi: 10.1111/j.1755-148X.2010.00773.x.

49.

Pictet-Spengler based synthesis of a bisarylmaleimide glycogen synthase kinase-3 inhibitor.

Magnus NA, Ley CP, Pollock PM, Wepsiec JP.

Org Lett. 2010 Aug 20;12(16):3700-3. doi: 10.1021/ol101405g.

PMID:
20704418
50.

Surgical treatment of septic jugular thrombophlebitis in nine horses.

Russell TM, Kearney C, Pollock PJ.

Vet Surg. 2010 Jul;39(5):627-30. doi: 10.1111/j.1532-950X.2010.00683.x. Epub 2010 Apr 29.

PMID:
20459491

Supplemental Content

Loading ...
Support Center